Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02197624 · ClinicalTrials.gov registry record
Genetic Variants and Iron Absorption
A clinical trial, sponsored by Cornell University.
- Completed
- Registry status
- 57
- Enrollment target
NCT02197624: Completed study, sponsored by Cornell University.
NCT02197624 is a clinical trial that has completed, run by Cornell University. The registered enrollment target is 57 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02197624 has completed, sponsored by Cornell University.
- COMPLETED
- Registry status
- 57 participants
- Enrollment target
Study Summary
The two specific aims of this study are: 1) to assess the impact of a genetic variant on iron status; 2) to assess the impact of a genetic variant on non-heme absorption among Asian women. The investigators hypothesize that the genetic variant could enhance iron status and iron absorption in Asian women.
Primary Outcome
At the participant's visit to the laboratory, a 10 mL blood sample was collected. The blood sample was used for determining genotype.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2012-06 |
| Est. Completion | 2014-05 |
What the finished NCT02197624 record still lists
NCT02197624 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 57 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02197624 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02197624 about?
NCT02197624 is a clinical study titled "Genetic Variants and Iron Absorption". The two specific aims of this study are: 1) to assess the impact of a genetic variant on iron status; 2) to assess the impact of a genetic variant on non-heme absorption among Asian women. The investigators hypothesize that the genetic variant could enhance iron status and iron absorption in Asian w...
What is the current status of trial NCT02197624?
This trial is currently completed. The enrollment target is 57 participants. The study started on 2012-06. Estimated completion is 2014-05.
Who is sponsoring clinical trial NCT02197624?
This trial is sponsored by Cornell University, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia